MedPath

Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-

Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity

Phase 2
Completed
Conditions
Cisplatin Nephrotoxicity
Interventions
First Posted Date
2016-05-04
Last Posted Date
2017-01-24
Lead Sponsor
Ain Shams University
Target Recruit Count
52
Registration Number
NCT02760901

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Phase 1
Completed
Conditions
Head and Neck Cancer
Interventions
Drug: Pembrolizumab
Radiation: Radiation Therapy
Drug: Cisplatin
First Posted Date
2016-05-03
Last Posted Date
2021-03-12
Lead Sponsor
Vinita Takiar
Target Recruit Count
9
Registration Number
NCT02759575
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2
Completed
Conditions
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2016-04-28
Last Posted Date
2024-12-10
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
35
Registration Number
NCT02754726
Locations
🇺🇸

Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States

Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy

Phase 2
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
First Posted Date
2016-04-27
Last Posted Date
2016-04-27
Lead Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Target Recruit Count
60
Registration Number
NCT02753140

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Phase 2
Terminated
Conditions
Esophageal
Interventions
First Posted Date
2016-04-25
Last Posted Date
2022-07-29
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
70
Registration Number
NCT02749526
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma, Non-Hodgkin's
Interventions
First Posted Date
2016-04-25
Last Posted Date
2021-04-13
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
30
Registration Number
NCT02750670
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Phase 3
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
First Posted Date
2016-04-19
Last Posted Date
2021-12-21
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
203
Registration Number
NCT02743923
Locations
🇳🇱

Haga, Den Haag, Netherlands

🇳🇱

Spaarne Gasthuis, Hoofddorp, Netherlands

🇳🇱

Medisch Centrum Leeuwarden, Leeuwarden, Netherlands

and more 25 locations

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Phase 2
Conditions
Oesophageal Cancer
Interventions
First Posted Date
2016-04-18
Last Posted Date
2018-10-25
Lead Sponsor
Lisette Nixon
Target Recruit Count
584
Registration Number
NCT02741856
Locations
🇬🇧

Bristol Haematology & Oncology, Bristol, United Kingdom

🇬🇧

Aberdeen Royal Infirmary, Aberdeen, United Kingdom

🇬🇧

Velindre Cancer Care Centre, Cardiff, United Kingdom

and more 23 locations

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

First Posted Date
2016-04-18
Last Posted Date
2021-12-07
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
39
Registration Number
NCT02741388
Locations
🇫🇷

CHU Dijon, Dijon, France

🇫🇷

CHRU de Lille - Hôpital Claude Huriez, Lille, France

🇧🇪

Institut Jules Bordet, Bruxelles, Belgium

and more 5 locations

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Phase 2
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Hypopharyngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant
p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oral Cavity Verrucous Carcinoma
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
First Posted Date
2016-04-12
Last Posted Date
2024-08-09
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
189
Registration Number
NCT02734537
Locations
🇺🇸

IU Health North Hospital, Carmel, Indiana, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

🇺🇸

Sanford Broadway Medical Center, Fargo, North Dakota, United States

and more 635 locations
© Copyright 2025. All Rights Reserved by MedPath